Following the third committee discussion of this appraisal on 26 March 2019, the Appraisal Committee has prepared a Final Appraisal Document (FAD) on ocrelizumab for treating primary progressive multiple sclerosis and submitted it to the Institute.
The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.
Please note that the appeal period for this appraisal will close at 5pm, 22 May 2019
This page was last updated: